{"commentary":{"count":187,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":127,"youtube":34,"podcast":24,"x_video":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05091567\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IMforte","nct_id":"NCT05091567","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imforte-nct05091567. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"IMforte","arms":[{"description":"Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.\n\nMaintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle in combination with lurbinectedin on Day 1 of each 21-day cycle.","label":"Arm A: Atezolizumab+Lurbinectedin","type":"EXPERIMENTAL"},{"description":"Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.\n\nMaintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle.","label":"Arm B: Atezolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":["Jazz Pharmaceuticals"],"completion_date":{"date":"2028-02-28","type":"ESTIMATED"},"conditions":["Small-Cell Lung Cancer"],"enrollment":{"count":660,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Lurbinectedin","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Etoposide","type":"DRUG"}],"last_update":"2026-09-09","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-07-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)","timeFrame":"Up to 26 months"},{"measure":"Randomized Phase: Overall Survival (OS)","timeFrame":"Up to 26 months"}],"references":[{"citation":"Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, Majem M, Sendur MAN, Czyzewicz G, Caro RB, Lee KH, Johnson ML, Karadurmus N, Grohe C, Baka S, Csoszi T, Ahn JS, Califano R, Yang TY, Kemal Y, Ballinger M, Cuchelkar V, Graupner V, Lin YC, Chakrabarti D, Bhatt K, Cai G, Iannone R, Reck M; IMforte investigators. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025 Jun 14;405(10495):2129-2143. doi: 10.1016/S0140-6736(25)01011-6. Epub 2025 Jun 2.","pmid":"40473449","type":"DERIVED"}],"start_date":{"date":"2021-11-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05091567"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imforte-nct05091567"}